We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

Spotlight Therapeutics, a Bay Area biotech company that raised $66 million from investors, including GV, has shut down.

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, ...

Recent innovations in DNA-modifying will revolutionize the treatment of many diseases and prompt crucial discussions.

In my work as a cancer researcher, I study the underlying mechanisms of how tumors develop and resist treatment. By ...